Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-08-23

AUTHORS

Jeffrey J. Link, John J. Warner, James A. de Lemos

ABSTRACT

Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions. More... »

PAGES

303-309

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12170-007-0049-x

DOI

http://dx.doi.org/10.1007/s12170-007-0049-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015175986


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Link", 
        "givenName": "Jeffrey J.", 
        "id": "sg:person.01023212521.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023212521.16"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Warner", 
        "givenName": "John J.", 
        "id": "sg:person.0774277534.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774277534.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, HA 9.133, 75390-9047, Dallas, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, HA 9.133, 75390-9047, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Lemos", 
        "givenName": "James A.", 
        "id": "sg:person.0626126332.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626126332.61"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2007-08-23", 
    "datePublishedReg": "2007-08-23", 
    "description": "Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12170-007-0049-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1039476", 
        "issn": [
          "1932-9520", 
          "1932-9563"
        ], 
        "name": "Current Cardiovascular Risk Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "1"
      }
    ], 
    "keywords": [
      "acute coronary syndrome", 
      "percutaneous coronary intervention", 
      "coronary syndrome", 
      "coronary intervention", 
      "unfractionated heparin", 
      "weight heparin", 
      "ST-elevation myocardial infarction", 
      "elevation acute coronary syndrome", 
      "clear mortality benefit", 
      "adjunctive antithrombin therapy", 
      "course of enoxaparin", 
      "safety of enoxaparin", 
      "antithrombin therapy", 
      "mortality benefit", 
      "myocardial infarction", 
      "enoxaparin", 
      "patients", 
      "syndrome", 
      "heparin", 
      "standard duration", 
      "intervention", 
      "recent data", 
      "Recent studies", 
      "past year", 
      "bivalirudin", 
      "infarction", 
      "fondaparinux", 
      "important studies", 
      "therapy", 
      "study", 
      "duration", 
      "safety", 
      "years", 
      "course", 
      "role", 
      "benefits", 
      "alternative", 
      "update", 
      "data", 
      "superiority"
    ], 
    "name": "Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update", 
    "pagination": "303-309", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015175986"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12170-007-0049-x"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12170-007-0049-x", 
      "https://app.dimensions.ai/details/publication/pub.1015175986"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_452.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12170-007-0049-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12170-007-0049-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12170-007-0049-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12170-007-0049-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12170-007-0049-x'


 

This table displays all metadata directly associated to this object as RDF triples.

110 TRIPLES      21 PREDICATES      65 URIs      57 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12170-007-0049-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N86d86bbb1ee14367a65a85cd5c88a184
4 schema:datePublished 2007-08-23
5 schema:datePublishedReg 2007-08-23
6 schema:description Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree false
10 schema:isPartOf N2f63091a3ae14b1e8a3fa6e78d4dd710
11 N44e912fcd5834f1cbc8064956ac17ba7
12 sg:journal.1039476
13 schema:keywords Recent studies
14 ST-elevation myocardial infarction
15 acute coronary syndrome
16 adjunctive antithrombin therapy
17 alternative
18 antithrombin therapy
19 benefits
20 bivalirudin
21 clear mortality benefit
22 coronary intervention
23 coronary syndrome
24 course
25 course of enoxaparin
26 data
27 duration
28 elevation acute coronary syndrome
29 enoxaparin
30 fondaparinux
31 heparin
32 important studies
33 infarction
34 intervention
35 mortality benefit
36 myocardial infarction
37 past year
38 patients
39 percutaneous coronary intervention
40 recent data
41 role
42 safety
43 safety of enoxaparin
44 standard duration
45 study
46 superiority
47 syndrome
48 therapy
49 unfractionated heparin
50 update
51 weight heparin
52 years
53 schema:name Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update
54 schema:pagination 303-309
55 schema:productId N494197dbeb7e4e588941427c6a4f2d2a
56 N733b5e7183a944928b81b0500868136b
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015175986
58 https://doi.org/10.1007/s12170-007-0049-x
59 schema:sdDatePublished 2022-01-01T18:18
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Nea6b9d164e0e41d7b439968be9a95cb4
62 schema:url https://doi.org/10.1007/s12170-007-0049-x
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N2f63091a3ae14b1e8a3fa6e78d4dd710 schema:volumeNumber 1
67 rdf:type schema:PublicationVolume
68 N3fddab61074a461cbc086fe61205674d rdf:first sg:person.0774277534.44
69 rdf:rest N682d6fb778654fa8b24945c199338316
70 N44e912fcd5834f1cbc8064956ac17ba7 schema:issueNumber 4
71 rdf:type schema:PublicationIssue
72 N494197dbeb7e4e588941427c6a4f2d2a schema:name dimensions_id
73 schema:value pub.1015175986
74 rdf:type schema:PropertyValue
75 N682d6fb778654fa8b24945c199338316 rdf:first sg:person.0626126332.61
76 rdf:rest rdf:nil
77 N733b5e7183a944928b81b0500868136b schema:name doi
78 schema:value 10.1007/s12170-007-0049-x
79 rdf:type schema:PropertyValue
80 N86d86bbb1ee14367a65a85cd5c88a184 rdf:first sg:person.01023212521.16
81 rdf:rest N3fddab61074a461cbc086fe61205674d
82 Nea6b9d164e0e41d7b439968be9a95cb4 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
85 schema:name Medical and Health Sciences
86 rdf:type schema:DefinedTerm
87 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
88 schema:name Clinical Sciences
89 rdf:type schema:DefinedTerm
90 sg:journal.1039476 schema:issn 1932-9520
91 1932-9563
92 schema:name Current Cardiovascular Risk Reports
93 schema:publisher Springer Nature
94 rdf:type schema:Periodical
95 sg:person.01023212521.16 schema:familyName Link
96 schema:givenName Jeffrey J.
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023212521.16
98 rdf:type schema:Person
99 sg:person.0626126332.61 schema:affiliation grid-institutes:grid.267313.2
100 schema:familyName de Lemos
101 schema:givenName James A.
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626126332.61
103 rdf:type schema:Person
104 sg:person.0774277534.44 schema:familyName Warner
105 schema:givenName John J.
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774277534.44
107 rdf:type schema:Person
108 grid-institutes:grid.267313.2 schema:alternateName University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, HA 9.133, 75390-9047, Dallas, TX, USA
109 schema:name University of Texas Southwestern Medical Center, 5909 Harry Hines Boulevard, HA 9.133, 75390-9047, Dallas, TX, USA
110 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...